QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, June 24, 2009, 29(25):7957-7965; doi:10.1523/JNEUROSCI.1339-09.2009

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in J. Neurosci. Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Wilcock, D. M. Articles by Colton, C. A. PubMed PubMed Citation Articles by Wilcock, D. M. Articles by Colton, C. A. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Medline Plus Health Information Alzheimer's Disease

 Previous Article  |  Next Article 

Neurobiology of Disease
Amyloid Reduction by Amyloid-β Vaccination Also Reduces Mouse Tau Pathology and Protects from Neuron Loss in Two Mouse Models of Alzheimer's Disease

Donna M. Wilcock,¹ Nastaran Gharkholonarehe,¹ William E. Van Nostrand,² Judianne Davis,² Michael P. Vitek,¹ and Carol A. Colton¹

¹Division of Neurology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, and ²Department of Medicine, Stony Brook University, Stony Brook, New York 11794

Correspondence should be addressed to Donna M. Wilcock, Division of Neurology, Department of Medicine, Duke University Medical Center, Bryan Research Building, Box 2900, Research Drive, Durham, NC 27710. Email: donna.wilcock{at}duke.edu

Shown to lower amyloid deposits and improve cognition in APP transgenic mouse models, immunotherapy appears to be a promising approach for the treatment of Alzheimer's disease (AD). Due to limitations in available animal models, however, it has been unclear whether targeting amyloid is sufficient to reduce the other pathological hallmarks of AD—namely, accumulation of pathological, nonmutated tau and neuronal loss. We have now developed two transgenic mouse models (APPSw/NOS2^–/– and APPSwDI/NOS2^–/–) that more closely model AD. These mice show amyloid pathology, hyperphosphorylated and aggregated normal mouse tau, significant neuron loss, and cognitive deficits. Aβ_1–42 or KLH vaccinations were started in these animals at 12 months, when disease progression and cognitive decline are well underway, and continued for 4 months. Vaccinated APPSwDI/NOS2^–/– mice, which have predominantly vascular amyloid pathology, showed a 30% decrease in brain Aβ and a 35–45% reduction in hyperphosphorylated tau. Neuron loss and cognitive deficits were partially reduced. In APPSw/NOS2^–/– vaccinated mice, brain Aβ was reduced by 65–85% and hyperphosphorylated tau by 50–60%. Furthermore, neurons were completely protected, and memory deficits were fully reversed. Microhemorrhage was observed in all vaccinated APPSw/NOS2^–/– mice and remains a significant adverse event associated with immunotherapy. Nevertheless, by providing evidence that reducing amyloid pathology also reduces nonmutant tau pathology and blocks neuron loss, these data support the development of amyloid-lowering therapies for disease-modifying treatment of AD.

---

Received March 19, 2009; revised May 7, 2009; accepted May 11, 2009.

Correspondence should be addressed to Donna M. Wilcock, Division of Neurology, Department of Medicine, Duke University Medical Center, Bryan Research Building, Box 2900, Research Drive, Durham, NC 27710. Email: donna.wilcock{at}duke.edu

Related articles in J. Neurosci.:

This Week in The Journal

J. Neurosci. 2009 29: i. [Full Text]  

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help